Figure S2 from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

S2: IAP antagonist treatment skewsT-cell development toward the CD8 lineage in fetal thymic organ culture (FTOC).</p

Figure S1 from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

S1: Structure of IAP antagonists</p

Figure S3 from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

S3: IAP antagonism alone does not induce apoptosis of iNKT cells or conventional T cells.</p

Supplemental Figure Legends from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

Figure legends</p

Figure S4 from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

S4: CD1d knockout mice show a significant contribution of the costimulatory effects of LBW-242 on cytokine production by CD4+ T cells.</p

Supplementary Figure S1 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S1. B3 binds to PD-L1 on multiple tumor types.</p

Supplementary Figure Legends from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

Supplementary Figure Legends from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHH

Supplementary Figure S3 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S3. Single agent treatment with B3 does not alter B16 growth in vivo.</p

Supplementary Figure S5 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S5. Combination B3-IL2 and A12-IFNγ has additive benefit over either agent alone.</p

Supplementary Figure S6 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S6. A12-IFNγ alters the tumor microenvironment in KPC organoid model of pancreatic cancer.</p